Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026

Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...

Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026

Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for...

Company Drug

CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study

Fineline Cube Feb 4, 2026

China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026

Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...

Company Drug

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

Fineline Cube Feb 4, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Fineline Cube Feb 4, 2026

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...

Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge

Fineline Cube Feb 4, 2026

Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...

Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026

Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...

Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026

Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...

Company Deals

TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline

Fineline Cube Feb 4, 2026

TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...

Company Drug

BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial

Fineline Cube Feb 4, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...

Company Drug

AbbVie Files Rinvoq for Vitiligo Approval in US and EU

Fineline Cube Feb 4, 2026

AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...

Company Drug

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Fineline Cube Feb 4, 2026

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...

Company Drug

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer

Fineline Cube Feb 4, 2026

Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...

Company

Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data

Fineline Cube Feb 4, 2026

Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026

Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Fineline Cube Feb 3, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the U.S. Food and Drug Administration...

Posts pagination

1 … 72 73 74 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.